23,428 Shares in Roivant Sciences Ltd. $ROIV Acquired by Forum Financial Management LP

Forum Financial Management LP purchased a new position in Roivant Sciences Ltd. (NASDAQ:ROIV) during the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 23,428 shares of the company’s stock, valued at approximately $264,000.

Several other hedge funds and other institutional investors also recently bought and sold shares of ROIV. CWM LLC increased its holdings in Roivant Sciences by 44.6% in the 2nd quarter. CWM LLC now owns 2,984 shares of the company’s stock worth $34,000 after buying an additional 920 shares during the period. Russell Investments Group Ltd. increased its holdings in Roivant Sciences by 94.8% in the 1st quarter. Russell Investments Group Ltd. now owns 4,588 shares of the company’s stock worth $46,000 after buying an additional 2,233 shares during the period. GAMMA Investing LLC increased its holdings in Roivant Sciences by 83.0% in the 1st quarter. GAMMA Investing LLC now owns 6,493 shares of the company’s stock worth $66,000 after buying an additional 2,945 shares during the period. UMB Bank n.a. increased its holdings in Roivant Sciences by 42.0% in the 2nd quarter. UMB Bank n.a. now owns 5,883 shares of the company’s stock worth $66,000 after buying an additional 1,740 shares during the period. Finally, PNC Financial Services Group Inc. increased its holdings in Roivant Sciences by 44.8% in the 1st quarter. PNC Financial Services Group Inc. now owns 10,248 shares of the company’s stock worth $103,000 after buying an additional 3,169 shares during the period. Institutional investors and hedge funds own 64.76% of the company’s stock.

Insider Transactions at Roivant Sciences

In related news, CEO Eric Venker sold 118,418 shares of Roivant Sciences stock in a transaction on Friday, October 17th. The shares were sold at an average price of $17.06, for a total value of $2,020,211.08. Following the sale, the chief executive officer owned 1,504,959 shares of the company’s stock, valued at approximately $25,674,600.54. This trade represents a 7.29% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Over the last 90 days, insiders have sold 5,228,958 shares of company stock valued at $76,447,638. 10.80% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on ROIV. Weiss Ratings upgraded shares of Roivant Sciences from a “sell (d+)” rating to a “hold (c-)” rating in a report on Saturday. JPMorgan Chase & Co. raised their price objective on shares of Roivant Sciences from $16.00 to $20.00 and gave the stock an “overweight” rating in a research note on Thursday, September 18th. Citigroup began coverage on shares of Roivant Sciences in a research note on Tuesday, September 2nd. They set a “buy” rating and a $16.00 price objective on the stock. Guggenheim raised their price objective on shares of Roivant Sciences from $15.00 to $21.00 and gave the stock a “buy” rating in a research note on Thursday, September 18th. Finally, HC Wainwright raised their price objective on shares of Roivant Sciences from $18.00 to $20.00 and gave the stock a “buy” rating in a research note on Thursday, September 18th. One equities research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $19.94.

Roivant Sciences Stock Performance

Roivant Sciences stock opened at $18.22 on Monday. The company’s fifty day moving average price is $14.60 and its 200 day moving average price is $12.34. Roivant Sciences Ltd. has a 1 year low of $8.73 and a 1 year high of $18.42. The stock has a market capitalization of $12.44 billion, a P/E ratio of -26.03 and a beta of 1.20.

Roivant Sciences Company Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.